JPMorgan Chase & Co. Cuts Chemours (NYSE:CC) Price Target to $15.00

Chemours (NYSE:CC) had its price target decreased by JPMorgan Chase & Co. from $22.00 to $15.00 in a report published on Thursday,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the specialty chemicals company’s stock.

Several other brokerages also recently commented on CC. Royal Bank Of Canada cut their price target on shares of Chemours from $26.00 to $22.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. BMO Capital Markets decreased their price objective on shares of Chemours from $26.00 to $18.00 and set an “outperform” rating for the company in a research note on Thursday. Morgan Stanley set a $18.00 target price on Chemours in a research report on Monday, August 10th. Weiss Ratings cut Chemours from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, August 6th. Finally, Alembic Global Advisors reiterated an “overweight” rating and issued a $30.00 price target on shares of Chemours in a report on Wednesday, May 13th. Five equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $20.10.

Chemours Stock Up 3.6%

NYSE CC opened at $15.81 on Thursday. The company has a quick ratio of 0.88, a current ratio of 1.66 and a debt-to-equity ratio of 18.98. Chemours has a 52 week low of $10.44 and a 52 week high of $28.67. The firm has a market capitalization of $2.38 billion, a price-to-earnings ratio of -8.28 and a beta of 1.43. The company has a fifty day moving average of $18.54 and a two-hundred day moving average of $20.00.

Chemours (NYSE:CC) last announced its earnings results on Tuesday, August 4th. The specialty chemicals company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $0.49 by ($0.07). The firm had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.65 billion. Chemours had a negative net margin of 5.00% and a positive return on equity of 60.64%. The company’s revenue was down 1.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($2.54) EPS. On average, analysts predict that Chemours will post 0.88 earnings per share for the current year.

Chemours Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Friday, August 14th will be issued a $0.0875 dividend. The ex-dividend date is Friday, August 14th. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.2%. Chemours’s dividend payout ratio is presently -18.32%.

Insider Buying and Selling

In related news, CEO Denise Dignam purchased 3,378 shares of Chemours stock in a transaction that occurred on Tuesday, August 11th. The shares were bought at an average price of $14.95 per share, with a total value of $50,501.10. Following the purchase, the chief executive officer directly owned 339,916 shares of the company’s stock, valued at approximately $5,081,744.20. This represents a 1.00% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Calderon Gerardo Familiar acquired 1,935 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The shares were bought at an average price of $15.53 per share, with a total value of $30,050.55. Following the acquisition, the insider directly owned 58,547 shares in the company, valued at $909,234.91. This represents a 3.42% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 8,663 shares of company stock valued at $130,601 in the last 90 days. Company insiders own 0.85% of the company’s stock.

Institutional Trading of Chemours

Institutional investors and hedge funds have recently modified their holdings of the stock. Baird Financial Group Inc. bought a new position in Chemours in the first quarter worth approximately $148,000. Royal Bank of Canada raised its position in Chemours by 6.8% during the 1st quarter. Royal Bank of Canada now owns 585,702 shares of the specialty chemicals company’s stock valued at $7,926,000 after purchasing an additional 37,382 shares in the last quarter. AQR Capital Management LLC bought a new stake in Chemours during the 1st quarter valued at $161,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Chemours by 149.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,243 shares of the specialty chemicals company’s stock worth $593,000 after buying an additional 25,899 shares during the period. Finally, Empowered Funds LLC purchased a new stake in shares of Chemours in the 1st quarter worth $403,000. Institutional investors own 76.26% of the company’s stock.

Key Stories Impacting Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours is expanding its low-GWP Opteon refrigerant portfolio to address rising cooling demand from AI-driven data centers. The initiative could support growth in a higher-demand market while aligning with customers’ decarbonization goals. Zacks article on Chemours refrigerants for data centers
• Positive Sentiment: CEO Denise Dignam bought 3,378 shares for approximately $50,500, while insider Gerardo Familiar Calderon purchased 1,935 shares for roughly $30,000. The open-market purchases may suggest that insiders view the recent share-price weakness as an opportunity. SEC filing on CEO purchase SEC filing on insider purchase
• Neutral Sentiment: BMO Capital Markets cut its price target from $26 to $18 but maintained an “outperform” rating, leaving implied upside while signaling reduced expectations. The broader analyst consensus remains “hold,” with an average target near $20.10.
• Negative Sentiment: A securities-fraud investigation involving Chemours was announced, creating a potential legal and reputational overhang for shareholders. The announcement does not establish wrongdoing, but it may increase uncertainty around the company.
• Negative Sentiment: JPMorgan lowered its price target from $22 to $15 and kept a “neutral” rating, while Zacks Research downgraded the stock from “strong buy” to “strong sell.” These actions reinforce concerns following Chemours’ recent quarterly EPS and revenue misses. Benzinga report on JPMorgan target cut Zacks rating report

Chemours Company Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.